Oncolys BioPharma Inc.
Notice Regarding Recognition of Non-operating Income and Non-operating Expenses
For the cumulative third quarter period (2026/1/1–2026/9/30), non-operating income of 12 million yen and non-operating expenses of 19 million yen were recorded. Main factors include foreign exchange gains and interest income. The impact is as stated in the Financial Summary for the third quarter of the fiscal year ending December 2026 [Japanese GAAP] (non-consolidated). The same amounts of income and expenses were also recorded for the period July 1, 2026–September 30, 2026.
Key Figures
- Non-operating income: 12 million yen
- Non-operating expenses: 19 million yen
- Period: 2026/1/1–2026/9/30 (cumulative third quarter period)
- Income breakdown: Interest income received 8 million yen, Foreign exchange gains 3 million yen
- Expense breakdown: Interest expense paid 12 million yen, Amortization of restricted stock compensation 4 million yen
AI要約
Overview
For the cumulative third quarter period of the fiscal year ending December 2026 (January 1, 2026–September 30, 2026), non-operating income of 12 million yen and non-operating expenses of 19 million yen were recorded. Major income items were interest income received and foreign exchange gains; expenses were due to interest expense paid and amortization of stock-based compensation, among others. The amounts of impact are described in the separately published Financial Summary.
Future Impact and Notes
This matter is disclosed as stated in the Financial Summary published on November 6, 2026. Non-operating profit and loss may fluctuate going forward depending on foreign exchange movements and interest rate trends.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
